Scholar Rock, Inc.

Christopher Littlefield

Thomas Schurpf

Abhishek Datta

Justin W Jackson

Stefan Wawersik

Matthew Salotto

Caitlin Stein

Gregory John Carven

Alan J Buckler

Andrew Avery

Allan Capili

Kevin B Dagbay

Christopher Chapron

Julia McCreary

Anthony Cooper

Adam Fogel

Frederick Streich, Jr

George Coricor

Constance Martin

Susan Lin

Anthony A Cooper

Gregory J Carven

Alan Buckler

Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.

LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors

Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ inhibitor for a subject in need thereof are also provided.

LTBP complex-specific inhibitors of TGFβ and uses thereof

Isoform-selective TGFB1 inhibitors and use thereof

Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF&#x3b2; and/or LTBP3-TGF&#x3b2;. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF&#x3b2; activation, and treating subjects suffering from TGF&#x3b2;-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF&#x3b2; inhibitor for a subject in need thereof are also provided.

LTBP complex-specific inhibitors of TGF&#x3b2; and uses thereof

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF&#x3b2;1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Isoform-selective TGF&#x3b2;1 inhibitors and use thereof

Growing community of inventors

Marblehead, MA, United States of America

Christopher Littlefield